Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Canadian-under $3.00 Stock-Picking Challenge -- Ignore unavailable to you. Want to Upgrade?

To: Al Collard who wrote (9226)	9/3/2002 8:18:31 AM
From: Chuca Marsh	Read Replies (2) \| Respond to of 11802

Can I switch my pick to COM-T - the chart does not show it had changed its name to Cardiome Pharma from Nortran Pharma a while back. Old NRT. Please delete the RUP. If allowed. Chucka PS - My dad had pased with this condition a decade ago( only affecting his last few years ), it was suggested that he had been influenced with the onset of the condition being a victum of Rheumatic Fever as a young person. Just in case others need to know. If they had childhood Rhm. Fever. News says it all and the vol says more on recent days: Cardiome Pharma Corp (2) - News Release Cardiome gives patients RSD1235 for phase II study Cardiome Pharma Corp (2) COM Shares issued 28,308,098 Jul 9 2002 close $ 1.95 Wednesday July 10 2002 News Release Mr. Robert Rieder reports CARDIOME COMPLETES PATIENT DOSING FOR RSD1235 Cardiome Pharma has completed dosing of patients in its phase II proof-of-efficacy clinical trial with its atrial antiarrhythmic drug candidate RSD1235. The placebo-controlled study is designed to determine the ability of intravenously administered doses of RSD1235 to terminate recent-onset atrial fibrillation. The company will announce the results of the study after completion of patient followups, audits of study sites and analysis of the database expected in September, 2002. Atrial fibrillation is a condition in which the atria or storage chambers of the heart beat rapidly and erratically. Left untreated, the condition can cause stroke or ultimately, congestive heart failure. Approximately six million patients in the developed world (the United States, Europe, Japan) suffer occasionally or chronically from atrial fibrillation. "We are pleased with having achieved completion of dosing within our expected timelines," said Dr. Alan Ezrin, chief scientific officer. "More important, we are grateful to our investigators in Canada and the United States for their commitment and enthusiasm in completing this challenging study." The primary endpoint of the phase II study was termination of atrial fibrillation within 30 minutes of infusion of study drug. RSD1235 is currently formulated for intravenous use in hospital. The placebo-controlled, double-blinded study was conducted at 21 sites throughout North America. RSD1235 is a proprietary drug designed to treat atrial fibrillation. Its mechanism of action involves blockade of multiple ion channels that play a key damaging role in atrial fibrillation. RSD1235 has a wide safety range in preclinical studies. In phase I clinical testing, no significant adverse events were observed, even at dosing levels higher than the expected effective dose. The medical community has consistently identified a pressing need for safer and more effective antiarrhythmic drugs. While significant progress has been made in understanding the mechanisms of AF, currently available drugs to treat AF lack sufficient efficacy and/or lack the ability to treat the diseased atria without affecting other healthy cells leading to serious side effects. The unique mechanism of action of RSD1235 suggests that the drug candidate may be able to treat atrial arrhythmia with a high margin of safety. I posted this on the 26th at SI: Message 17919215

To: Al Collard who wrote (9226)	9/3/2002 8:36:39 AM
From: Al Collard	Read Replies (1) \| Respond to of 11802

The Stock-Picking Challenge Picks For Week # 1: LATEST CASH ENTRANT STOCK #SHARES PRICE VALUE Al Collard IW-t 58,823 @$ .17 $ average joe CDO-v 76,923 @$ .13 $ Bearcatbob KOB-t 62,500 @$ .16 $ brian krause PGI-v 8,000 @$1.25 $ Buckey LIR-t 333,333 @$ .03 $ Carter B MOA-v 11,235 @$ .89 $ Ceedee AXA-t 17,241 @$ .58 $ Chucka Marsh COM-t 7,142 @$1.40 $ Daytek77 EV-v 30,303 @$ .33 $ diddlysquatz EYE.a-v 20,000 @$ .50 $ dsit MWA-t 76,923 @$ .13 $ Eva ELD-t 7,575 @$1.32 $ flourainne JBA-v 142,857 @$ .07 $ geoffb_si PBP-t 20,833 @$ .48 $ hx4 CNB-v 45,454 @$ .22 $ J.E.Currie BMD-v 52,631 @$ .19 $ JR. BBK-v 83,333 @$ .12 $ KC Jones EET-t 8,474 @$1.18 $ Killick CQV-v 50,000 @$ .20 $ Miner DMX-t 4,032 @$2.48 $ pull_da_trigger ONC-t 4,273 @$2.34 $ Rocket Red MPV-t 9,615 @$1.05 $ SAM-DAN YWW-v 142,857 @$ .07 $ Stephen O BI-t 5,405 @$1.85 $ The Osprey OEL-v 23,809 @$ .42 $ vds4 DML-v 66,666 @$ .15 $ X squared PAL-v 27,027 @$ .37 $